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Duodenal neuroendocrine tumours (d-NETs) are rare, but are increasing in incidence. Current ENETS 
guidelines advocate resection of all localised d-NETs. However, ‘watch and wait’ may be appropriate 
for some localised, small, grade 1, non-functioning, non-ampullary d-NETs. We evaluated whether 
patients with such d-NETs who chose ‘watch and wait’ involving regular endoscopic surveillance had 
equivalent disease-related outcomes to patients undergoing endoscopic or surgical resection.  
Methods  
Retrospective review of patients with histologically confirmed d-NETs at Liverpool ENETS Centre of 
Excellence 2007-2020.   
Results 
Sixty-nine patients were diagnosed with d-NET of which fifty were sporadic, non-functioning, non-
ampullary tumours. Patient treatment groups were similar in terms of age, gender, tumour location 
and grade, but unsurprisingly, larger tumours (median diameter 17mm (p<0.0001)) were found in the 
surgically treated group. Five patients underwent surgical resection with no evidence of tumour 
recurrence or disease-related death. Twelve patients underwent endoscopic resection, with one local 
recurrence detected during follow-up. Thirty patients (28 with d-NETs ≤10mm) underwent ‘watch and 
wait’ with resection only if tumours increased in size. The d-NETs in 28/30 patients remained stable or 
decreased in size over a median 27 months (IQR:15-48, R:3-98). In seven patients the d-NET was 
completely removed by avulsion during diagnostic biopsy and was not seen at subsequent endoscopies. 
Only two patients showed increased d-NET size during surveillance, of whom only one was fit for 
endoscopic resection. No NET-related deaths were documented during follow up. 
Conclusions 
All of the localised, ≤10mm, grade 1, non-functioning, non-ampullary d-NETs in this cohort behaved 
indolently with very low risks of progression and no tumour-related deaths. ‘Watch and wait’ therefore 




Duodenal neuroendocrine tumours (d-NETs) are a rare type of neuroendocrine cancer with a reported 
incidence of 2% of all gastrointestinal neuroendocrine tumours [1]. d-NETs are heterogeneous in terms 
of clinical presentation, histological characteristics and anatomical location and this is reflected by 
diverse biological behaviour and subsequent prognosis. 
Low grade, non-functioning tumours represent up to 60-98% of all d-NETs and this subgroup tends to 
have a more favourable prognosis[2]. Other functioning d-NETs include gastrinomas; 
somatostatinomas and gangliocytic paragangliomas while more aggressive poorly differentiated 
neuroendocrine carcinomas can also occur at this location[3]. Based on their location, d-NETs are 
categorised into ampullary and non-ampullary. Ampullary d-NETs exhibit more aggressive disease 
biology and have a different clinical, histological and immunohistochemical profile[4-6].  
The most recent ENETS treatment guidelines advocate resection for all d-NETs using either endoscopic 
or surgical techniques[7]. We recently published a systematic review of the management of localised 
low grade upper gastrointestinal NETs and found that a few studies had also reported favourable 
outcomes for patients who had not undergone resection of small, low grade non-functioning, non-
ampullary d-NETs[8]. Despite limited follow up data, Burke at al. [9]reported 12 patients who did not 
undergo any treatment with 11 patients being alive after 11 months of mean follow up. More recently, 
Min et al. [10]described 13 d-NET patients who underwent close endoscopic follow up with a mean 
follow up period of 37 months. Median size of the lesions was 4 mm and 5/13 lesions were 
unintentionally completely removed using diagnostic forceps biopsy. More importantly, no lymph node 
or distant metastases developed and no tumour-related deaths occurred during the entire follow-up 
period. 
The types of surgical resection employed for d-NETs, including distal gastrectomy and 
pancreaticoduodenectomy can be associated with significant morbidity and mortality[11, 12].  
Furthermore, endoscopic resection can be complicated by perforation or bleeding[13, 14]. 
Taking these risks into consideration and the likely favourable prognosis associated with many of these 
small, localised, grade 1 tumours, ‘watch and wait’ with regular endoscopic surveillance may be a viable 
alternative management strategy, especially in patients in whom the risks of surgical or endoscopic 




To perform a retrospective analysis of all patients with non-functioning, non-ampullary d-NETs at our 
centre to map the natural history of their disease and to evaluate whether patients who had undergone 
‘watch and wait’ involving periodic endoscopic surveillance rather than endoscopic or surgical resection 
had equivalent disease-related outcomes. 
 
Materials and Methods 
Patient selection 
All patients diagnosed with a histologically confirmed duodenal neuroendocrine tumour at the 
Liverpool ENETS Centre of Excellence between February 2007 - 2020 were identified and enrolled in a 
prospectively collected database. The characterisation of duodenal neuroendocrine tumour was based 
on the contemporaneous World Health Organisation classification of neuroendocrine tumours. Ethical 
approval was not required for this retrospective analysis of routinely collected data, but the project was 
registered and approved by the Audit Department of Liverpool University Hospitals NHS Foundation 
Trust. Data collected included patient demographics, tumour size, location, histological characteristics, 
radiological findings, plasma chromogranin A concentration, treatment plan and follow up. All cases 
were discussed at the NET multidisciplinary team meeting. 
Endoscopic assessment and resection 
All the patients were endoscopically assessed and followed up by two experienced NET physicians who 
are also consultant gastroenterologists (~90% of endoscopies performed by DMP and ~10% by ARM) in 
order to reduce interobserver variability. Polyps were assessed by white light endoscopy assisted by 
narrow band imaging on each occasion. Tumour size was estimated endoscopically by comparison with 
an opened pair of biopsy forceps (Single-Use Radial Jaw 4 - Boston Scientific, Hemel Hempstead, UK) 
and compared with photographss taken at previous endoscopies. Any persistent lesion during follow-
up endoscopy was biopsied on each occasion (including scars at the site of previous endoscopic 
resections). All endoscopic resections were performed by HLS. 
 
Treatment algorithm  
Patients who had localised, sporadic, non-functional, non-ampullary d-NETs measuring >10mm 
diameter were advised to undergo tumour resection, with endoscopic resection being recommended 
for tumours with a diameter 10-15mm and surgical resection for tumours with a diameter >15mm (Fig.  
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1). If a patient who had a grade 1 d-NET larger than 10mm or a grade 2 tumour  was considered to be 
unfit for resection due to the presence of significant comorbidities, they were offered surveillance 
instead. Patients who had small (≤10mm), localised, sporadic, non-functional, non-ampullary d-NETs 
with a Ki-67 index <3% were counselled regarding the risks and benefits of endoscopic surveillance and 
endoscopic resection, including the likely indolent course of these tumours, surveillance intervals and 
rescue strategies if needed. Within this cohort were some patients who had no endoscopic evidence of 
residual d-NET after initial avulsion using biopsy forceps and they were encouraged to undergo 
endoscopic surveillance rather than further resection. Patients who had persistent, small d-NETs at 
follow-up endoscopy and who were considered fit enough for endoscopic resection were counselled 
regarding the individualised relative risks and benefits of this approach versus endoscopic surveillance, 
and offered a choice of treatment.  
Patients in the endoscopic surveillance cohort underwent annual or biennial oesophago-gastro-
duodenoscopy (OGD). For patients undergoing endoscopic treatment, a follow-up examination was 
performed 4–6 months after the resection procedure. In cases where no residual lesions were found, 
follow-up examinations were recommended 12 months after the initial procedure and then annually 
or every two years thereafter. Some patients were not followed up long term due to the presence of 
severe comorbidities or their choice/non-attendance of appointments. 
All patients underwent cross sectional imaging the form of abdominal contrast-enhanced computerised 
tomography (CT) scan. Nuclear imaging in the form of 111Indium Octreotide scan or more recently 68Ga-
DOTATATE PET-CT scan was also undertaken in some patients, particularly when endoscopic or surgical 
intervention was being considered. Baseline plasma chromogranin A concentrations (normal range 
<60pmol/L) were measured in all patients. 
Statistics 
Statistical analysis was performed using GraphPad Prism version 8.4.0 for Windows, GraphPad 
Software, La Jolla California USA, www.graphpad.com. Patient and tumour characteristics were 
compared between groups using One Way ANOVA with Tukey’s correction and Fisher’s exact test 
where appropriate. Differences were considered significant at p <0.05. 
Results 
Characteristics of entire duodenal NET cohort 
In total, 69 patients were diagnosed with a d-NET at our centre over a 13-year period (Fig.  2). Nineteen 
patients were excluded from further analysis; six patients with ampullary NETs, five patients with 
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functional d-NETs or associated inherited syndromes such as Multiple Endocrine Neoplasia Type 1 or 
Neurofibromatosis and eight patients in whom a small d-NET was detected incidentally on histology 
after they had undergone surgery for an unrelated reason (Supplementary Table 1). 
Fifty patients were therefore diagnosed with sporadic, non-functional, non-ampullary d-NETs. Three of 
these patients did not undergo any follow up endoscopy or treatment due to patient choice, preference 
for local hospital follow up or because they were unfit for any intervention at the time of diagnosis and 
they were excluded from our analyses. Five of the remaining 47 patients underwent elective surgical 
resection based on the size of their tumours, 12 patients underwent planned endoscopic resection and 
30 patients were enrolled into an endoscopic surveillance programme. Patient demographics and 
tumour characteristics are described in Table 1.   
There were no statistically significant differences in patient age or gender amongst the three treatment 
groups. In terms of morphology, most tumours were solitary, located in D1 (90%) and at least 84% were 
grade 1. Patients undergoing endoscopic surveillance or endoscopic treatment had similar tumour 
sizes, whereas unsurprisingly the surgical cohort had significantly larger tumours with a median 
diameter of 17mm (IQR: 15-18mm, p<0.0001). Baseline plasma Chromogranin A concentrations were 
within the normal range in all patients. CT staging did not identify any lymph node or distant metastases 
at the time of diagnosis. Sixteen patients additionally underwent 111Indium Octreotide scan and twelve 
had a 68Ga-DOTATATE PET-CT scan. One patient had a somatostatin receptor avid portocaval lymph 
node, but he was unfit for surgical resection. He therefore underwent endoscopic and CT surveillance 
with evidence of stable disease for 3 years before he died as a result of one of his other illnesses.  A 
second patient showed evidence of possible tiny somatostatin receptor positive liver metastases, but 
structural liver lesions were not seen on MR scan and no disease progression was detected on 
subsequent imaging; his primary tumours also did not increase in size during follow up, his 
chromogranin A level did not increase and he remains asymptomatic on no treatment six years later. 
The functional imaging findings in this patient are therefore in retrospect thought to have been 
artefactual. 
Surgery 
Five patients underwent a surgical resection with a median tumour diameter of 17 mm (IQR:15-18mm) 
and median follow up 27.5 months (IQR: 16.4-62.8, R: 10.5-73.7). Peri-operative staging with CT scan 
and functional imaging did not demonstrate any lymph node or distant metastases in any of these 
patients. Four of the resected d-NETs were grade 1 and the grade is not available for one patient as 
surgery was performed prior to referral to our tertiary centre 10 years ago. Four of the patients did not 
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demonstrate any lymph node metastases on resected specimens, while one patient had N1 nodal 
involvement. No immediate post-operative complications were noted and no surgical specific related 
deaths were documented.  Two patients have been discharged after 5 years of follow up, two are still 
under follow-up as their resection was performed more recently and one patient has died and although 
the cause of death is not definitively known, it is not believed to be d-NET related. No tumour 
recurrences have been detected in this group. 
Endoscopic Resection  
Twelve patients underwent endoscopic resection (ER) using a variety of techniques (Table 2). One ER 
was performed in a patient with a d-NET >10mm in diameter, while 11 were performed in patients with 
d-NETs ≤10mm who elected to have endoscopic resection rather than ‘watch and wait’. Three of these 
12 procedures were complicated by perforation; one patient required emergency surgery whereas the 
other two cases were treated endoscopically with endoscopic clips and intravenous antibiotics. All 
these rescue measures were successful and there were no procedure related deaths. No significant 
haemorrhage occurred in any patient. Median follow up for this group was 47 months (IQR:34-66) and 
patients underwent regular endoscopic follow up with a median of five post EMR surveillance OGDs per 
patient (IQR:4-5). Eleven patients have shown no evidence of local tumour recurrence. A 4mm tumour 
was observed in one patient nine months after ER. This patient opted for ongoing endoscopic 
surveillance and up to four diminutive duodenal polyps have been found during seven subsequent 
surveillance OGDs over a follow-up period of 72 months . We therefore think that it is most likely that 
he has developed new d-NETs rather than having a true tumour recurrence. Eight patients have been 
discharged to date after a median follow up period of 47 months (IQR:41-61, R:13-81) having shown no 
evidence of residual tumour on follow up surveillance endoscopy or histology. No d-NET related deaths 
occurred, although two patients have died from unrelated conditions. 
Endoscopic Surveillance  
The remaining 30 patients were enrolled into a ‘watch and wait’ endoscopic surveillance programme 
(Fig.  3, Supplementary table 2). Twenty-seven of these fulfilled the criteria of having ≤10mm diameter 
and grade 1 d-NETs.Two patients who had grade 2 tumours were also included. One patient who had a 
15mm lesion and Ki67% of 4% opted for surveillance as he was synchronously diagnosed with and 
subsequently died from colorectal cancer and the second patient opted for suveillance  because his 
5mm, Ki67 8% d-NET was completely avulsed at the time of initial endoscopy. Another patient had a 
12mm grade 1 tumour, but he was unfit fior further intervention. All patients underwent at least one 
surveillance endoscopy with a median of two (IQR:1-4, R:1-7). The time interval from baseline to first 
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surveillance endoscopy was five months (IQR:3-7) and subsequent endoscopies were performed every 
12-15 months. Overall median follow-up was 27 months (IQR:15-48, R:3-98). Seven patients have had 
only a single follow up endoscopy and a follow up period of less than 12 months. In two cases, 
endoscopic surveillance was discontinued because these patients were found to also have metastatic 
colorectal cancer, one older patient was discharged as there was no residual endoscopic abnormality 
after avulsion of a 2mm d-NET using biopsy forceps, two patients declined the offer of further 
endoscopic surveillance and two patients are currently awaiting their next surveillance endoscopy, this 
having been delayed due to the current Covid-19 pandemic. 
Seven d-NETs (6 of which measured ≤5mm and including a grade 2 tumour) were unintentionally 
completely avulsed using diagnostic biopsy forceps at the time of initial endoscopy (most of which were 
performed outside our tertiary referral centre) with no residual tumour being seen on subsequent 
endoscopic follow up. This was supported by negative biopsies from the scar site in some cases. None 
of these tumours have recurred during subsequent follow up and no additional treatment has been 
required in any of these patients.  
Twenty-one of the other 23 tumours have remained stable or have decreased in size over time (median 
follow up 24 months, IQR:12-46, R:3-98). Three patients did not demonstrate a d-NET on first follow up 
endoscopy, but diminutive (<5mm) recurrent polyps were found at their 3rd or 4th surveillance 
endoscopies and have remained stable during subsequent surveillance. Eighteen patients have shown 
persistent polyps which have not increased in size during follow up. Only two patients were found to 
have an increase in the size of their lesions during surveillance. The first of these demonstrated an 
increase from 12mm to 20mm from baseline to first surveillance endoscopy in a time frame of 15 
months. He did not fulfil the entry criterion into ‘watch and wait‘ of having a ≤10mm d-NET, but he was 
not fit for any intervention and has remained under surveillance with no further increase in tumour size 
being detected over 30 months. The second patient was found to have an increase in tumour size from 
10mm at baseline to 13mm at first surveillance endoscopy 20 months later.  She therefore underwent 
an endoscopic resection of a D1, grade 1 lesion with an R0 resection margin (Fig.  3). She has continued 
under surveillance and there has been no subsequent evidence of endoscopic or histological 
recurrence. 
In addition to the cases described above who have had limited follow up, a further nine patients have 
been discharged to date from the surveillance programme. These patients either had no residual 
tumour on follow up endoscopy or had small lesions that remained stable over a median follow-up 
period of 43 months (IQR:33-52, R:26-98).  
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Other than the two patients whose baseline functional imaging scans have been discussed above, no 
patients in this cohort developed confirmed metastatic disease during follow up. Overall, five patients 
have died (three of these are known to be non-NET related and although the cause of death in two 
patients is unknown as they died at home or at their local hospital, they are not suspected to be NET 
related).  
Discussion 
Duodenal NETs are heterogeneous in terms of histological type, size, secretory status and anatomical 
location. Patient management plans therefore need to be personalised and take all these features into 
account. The current ENETS management guidelines recommend resection of all d-NETs, with the mode 
of resection being influenced largely by the size of the tumour [15, 16, 8]. A  recent study by Gamboa 
et al [17] supported this argument as the authors demonstrated improved overall survival with any type 
of resection regardless of tumour size when compared to no resection. However, although this study 
included non-functioning d-NETs the authors did not differentiate between ampullary and non-
ampullary lesions or take into consideration disease specific survival. Ampullary lesions are recognised 
as being more aggressive in terms of disease biology and prognosis when compared to non-ampullary 
d-NETs and surgical resection is therefore advocated for these lesions. In agreement with this, the only 
known d-NET-related deaths in our cohort occurred in patients who had ampullary tumours.  
The incidence of small non-ampullary d-NETs has increased over the last few decades with the advent 
of widespread diagnostic endoscopy and increased recognition of these lesions[18, 19]. However, 
reports of the natural history of non-ampullary d-NETs exist in only a handful of case reports and case 
series[9, 10, 20]. A recent study assessing risk factors for metastases for <20mm non-ampullary lesions 
identified lymphvascular invasion (LVI), tumour size >11mm  and  WHO grade 2 as a being risk factors 
for metastatic disease[21].  
It is being increasingly recognised that many non-ampullary d-NETs are detected incidentally and that 
typical patients are found to have asymptomatic, small, localised, low grade tumours. At our ENETS 
Centre of Excellence, we were aware of a number of patients who were not fit for endoscopic or surgical 
resection who showed a very indolent disease course over many years with no evidence of tumour 
growth, metastasis or d-NET related death. Such d-NETs may therefore have a similar natural history to 
that associated with small type I gastric NETs, where endoscopic surveillance rather than resection is 
now the generally recommended management option. We therefore hypothesised that in some cases 
(namely patients who have localised, ≤10mm diameter, non-functional, grade 1 d-NETs) tumour 
resection, with its associated risks, can be safely avoided. This option has been proposed for ‘early‘ well 
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differenciated grade 1 NETs at other sites, namely  the stomach, duodenum, rectum and pancreas [19]. 
Over recent years we have therefore had detailed discussions with such patients about the potential 
benefits and risks of tumour resection and a number of patients who either have had no evidence of 
residual d-NET after initial biopsy or who had significant comorbidities or anxieties about potential 
tumour resection have made an informed choice to have close endoscopic surveillance of their d-NET 
instead of endoscopic resection. We also offered endoscopic surveillance to two patients who had 
tumours outwith the selection criteria described above, but who were not fit for elective tumour 
resection. 
In this study, we have reviewed our experience of managing patients who have sporadic, localised, 
grade 1 , non-functioning, non-ampullary d-NETs and our use of a ‘watch and wait’ endoscopic 
surveillance programme as an alternative management strategy in some of these patients. In general, 
this programme had good compliance and a low attrition rate. The first surveillance endoscopy was 
usually planned for about 6 months after diagnosis to assess whether any residual duodenal lesion was 
still present and to assess the rate of growth of any persistent tumour. If the endoscopic appearances 
were stable, the surveillance interval was subsequently increased incrementally to 12-24 months.We 
detected a number of patients (7) in whom no residual endoscopic abnormality (other than a scar) was 
visible after avulsion biopsy of the polyp at the index endoscopy (median tumour size 4mm). None of 
these tumours recurred locally or at distant sites during subsequent follow up, so the absence of a 
persistent macroscopic lesion at this stage appears to be a very good prognostic feature. Our 
observations are therefore similar to those of Min et al. for this category of patient. Additional 
endoscopic resection of the scar site in this type of patient therefore does not appear to be necessary. 
It is important to note that although avulsion biopsy may successfully treat patients who have <5mm 
lesions, we do not advocate it as part of the treatment algorithm for d-NETs and formal endoscopic 
resection remains the gold standard. Over a 13-year period only two of the remaining 23 patients on 
our surveillance programme who had persistent duodenal lesions demonstrated an increase in the size 
of their d-NET during follow up. Both increases occurred from baseline to first surveillance OGD and 
this may have been due to the initial endoscopist at another hospital underestimating the size of the 
original lesion. Moreover, one of these patients did not fulfil the criterion of having a ≤10mm d-NET at 
baseline, but he was unfortunately unfit for intervention. Only one of these patients therefore 
proceeded to endoscopic resection and this was performed successfully. During the entire follow up 
period, no patients have been found to develop metastases and no known d-NET related deaths have 
occurred in the ‘watch and wait’ cohort. 
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Several patients in our series were either advised or elected to have tumour resection. Our experience 
using ER demonstrated a complication rate of 25%, which is significantly higher than the complication 
rate of 8.6% in the systematic review that we recently published. This could be attributed to our small 
cohort size, but confirms that endoscopic resection of a submucosal tumour at an intestinal site that 
has a thin wall does have a significant risk of complications. Nonetheless all cases of perforation were 
successfully salvaged and there were no procedure related deaths. Endoscopic resection was successful 
in the vast majority of patients (11/12) and no metastases or tumour related deaths were detected in 
any of these patients during follow up. One patient was found to have a recurrence at nine months 
after endoscopic resection. This lesion was only 4mm in size and it is distinctly possible that it may 
represent a new d-NET rather than a recurrence as he has subsequently undergone seven endoscopieds 
over a period of 72 months and these have demonstrated a number of diminutive d-NETs on each 
occasion.  
 We also had good outcomes in our surgical cohort with no significant short-term postoperative 
complications and again no postoperative tumour recurrences or tumour related deaths. This may be 
a reflection of our high-volume centre which has minimal morbidity and mortality for such procedures. 
However, we should not underestimate the long-term morbidity and quality of life in patients 
undergoing these major operations.  
Initial assessment of all patients included measurement of seum chromogrnain A concentration. 
Baseline chromogranin A levels for were within normal limits in all patients reflecting the modest 
sesitivity of this test for the diagnosis of small localised non-functioning d-NETs [22]. We did not 
measure serum Chromogranin A levels as part of the routine follow up of these patients, as several 
prospective studies have demonstrated that this is not useful [23]. 
There are no systematic studies of the ability of different modalities to localise duodenal NETs, except 
in patients with Zollinger Ellison Syndrome[2]. For the vast majority of patients with a duodenal NET 
who do not have a secretory clinical syndrome, upper gastrointestinal endoscopy is the most sensitive 
method for  tumour detection. We did not perform cross sectional imaging or functional imaging 
routinely for follow-up in the surveillance group. Almost all patients in this group had a CT scan as part 
of their initial diagnostic work up and only if there was a clinical concern was this repeated. Although 
lymph node metastases can occur in small lesions according to Hatta et al [21], the main risk factors for 
metastasis are LVI, tumour size 11-20mm, multiple tumours and grade 2 lesions. Almost all of the 
patients in our surveillance group did not demonstrate any of these risk factors and the ones who did 
have been highlighted and discussed. Furthermore, regarding functional imaging, we did not have a 
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strict protocol for assessing patients with functional imaging modalities unless further intervention was 
being considered in the form of endoscopic or surgical resection. Some patients in the surveillance 
group did have functional imaging and this was undertaken on a case by case basis. Factors that 
contributed to a decision to perform imaging were lesions >10mm, young patient age, patient anxiety 
and the availability of 68Ga DOTATATE PET/CT scans at our institution at the time. 
Our study has some obvious limitations, primarily related to its design. It is a retrospective, single 
centre, non-randomised study. The surveillance methods for d-NETs include assesment of polyp size 
which could be deemed subjective. In order to reduce interobserver  variability, only two experienced 
NET gastroenterologists undertook endoscopic assesssment and surveillance of these patients. 
Additionally, a standardised method of assessement was agreed using biopsy forceps and comparisons 
were made between images taken at each endoscopy. The median follow up in our surveillance group, 
is only 27 months as we have included patients who had less than 12 month follow up (e.g. those in 
whom surveillance has ahd to be postponed due to COVID-19). If those patients are excluded, the follow 
up period increases to 36 months (IQR: 21-51). We also have to take into consideration that we have 
safely discharged nine patients who had a much longer follow up period (median 43 months, IQR:33-
52, R:26-98). Lastly, when advocating a surveillance programme for d-NETs, life expectancy as well as 
concurrent comorbiditites should be taken into consideration. A different approach might be 
appropriate for a fit patient who has been diagnosed in his/her 40s or early 50s when compared to an 
elderly  patient who has significant comorbidities.In conclusion, the prognosis in our series of patients 
who had localised, small, grade 1, non-ampullary d-NETs and reasonably long follow up was excellent 
with no confirmed NET-related deaths in the entire cohort. Although those patients who had tumour 
resection had a good prognosis with no evidence of local tumour recurrence in 16/17 patients, no 
metastasis and no known tumour related deaths, similar outcomes were also observed in the majority 
of patients who underwent endoscopic surveillance on the ‘watch and wait’ programme. Moreover, 
the d-NETs in the endoscopic resection and endoscopic surveillance groups were of similar small size, 
with tumours measuring ≤10mm diameter being present in 11/12 and 28/30 cases in these groups 
respectively. Overall, our observations therefore support an emerging view that many small, sporadic, 
localised, grade 1, non-ampullary d-NETs have a very indolent disease course.  
As some previous papers have reported poor outcomes in a small proportion of d-NET patients, we 
would still advocate resection of all ampullary d-NETs, all non-ampullary NETs >10mm in diameter and 
all grade 2 or 3  d-NETs  as long as the patient is fit enough to undergo the appropriate procedure. 
However, as tumour resection can result in various short- and long-term complications, our data 
suggest that many patients who have ≤10mm sporadic, non-functional, non-ampullary d-NETs, 
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particularly the majority that are grade 1 can probably be safely managed by a ‘watch and wait’ strategy 
We would recommend surveillance initially at 6 months post diagnosis and as long as the lesion is stable 
then annually for three years and then every two years. Surveillance should be continued for as long as 
the patient remains fit for either endoscopic and/or surgical intervention. Regading the use of imaging 
during follow up, we would not advocate routinely performing CT or functional imaging studies unless 
there is a change in the clinical, endoscopic or histological apprearances. Most patients who are 
managed in this way appear to require no further intervention and in our series delayed tumour 
resection in the single patient who demonstrated an increase in d-NET size during follow up did not 
adversely affect her outcome. A large scale prospective randomised trial would be helpful to validate 
this approach. However, in view of the rarity of this tumour type, this may be difficult to conduct. We 
would therefore suggest that at present, it is reasonable to discuss the relative risks and benefits of 
‘watch and wait’ versus endoscopic resection in patients who have sporadic, ≤10mm, non-functional, 
non-ampullary  grade 1 d-NETs and that close endoscopic surveillance with an intention to resect if the 
tumour increases in size is likely to be a safe management approach in most patients. These criteria can 
potentially also be extended in terms of tumour size if an individual patient has a substantially increased 
risk for resection. As patients who undergo endoscopic resection usually also undergo regular 
endoscopic surveillance for a few years afterwards, this ‘watch and wait’ strategy is also unlikely to be 





We would like to thank University of Liverpool medical students Bethan Salmon and Pranu Ragatha 
for help with data extraction and Prof Fiona Campbell for confirmation of some histopathological 
findings. 
 
Statement of Ethics 
No ethical approval was required for this retrospective study, but it was approved by the audit 
department of Liverpool University Hospitals NHS Foundation Trust. 
 
Disclosure Statement 
DMP has acted as a consultant for Ipsen, Advanced Accelerator Applications and Laboratoire Mayoly 
Spindler and has received research funding from Trio Medicines UK. ARM has acted as a consultant for 
Ipsen. None of the other authors have any conflicts of interest to declare. 
 
Funding Sources 




KE acquisition of data; analysis and interpretation of data; statistical analysis; drafting of the 
manuscript; critical revision of the manuscript for important intellectual content 
ARM analysis and interpretation of data; critical revision of the manuscript for important intellectual 
content 
HLS analysis and interpretation of data; critical revision of the manuscript for important intellectual 
content 
CAD analysis and interpretation of data; critical revision of the manuscript for important intellectual 
content 
NH analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript 
for important intellectual content 
DMP study concept and design; analysis and interpretation of data; drafting of the manuscript; critical 





Fig. 1.  Flow diagram of evaluation and selection criteria for treatment groups of “watch and wait” and 
endoscopic or surgical resection. 
Fig. 2. Flow diagram of all d-NETs diagnoses at Liverpool ENETS CoE between 2007-2020. After initial 
allocation into treatment groups 42 patients underwent regular endoscopic surveillance. One patient 
recurred after ER and remained under surveillance and one patient in surveillance required an ER.  
Fig. 3. Polyp size on follow up OGDs of patients undergoing endoscopic surveillance. A: Patients that 
have remained entirely stable over serial OGDs, B: patients in whom d-NETs have reduced in size over 
time, C: patients whose d-NETs were completely avulsed by biopsy forceps at their initial endoscopy, 
D: patients demonstrating an increase in d-NET size during follow up.  
 
Table Legends 
Table 1: Demographics and tumour characteristics of all non-ampullary non-functioning d-NETs. 
Table 2: Patient, tumour characteristics and outcomes of patients undergoing endoscopic treatment. 
 
Supplementary Data 
Table 1: Excluded patients from analyses. Demographics, tumour characteristics and outcomes for 
patients in whom d-NETs were incidental findings, ampullary and functional tumours. 
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D1: first part of duodenum; D2: second part of duodenum; UK: unknown; G1: grade 1; G2: grade 2; G3: grade 
3; ES: Endoscopic Surveillance; ET: Endoscopic Treatment;   




























1 Female 56 D1 RBL ER 5 5 1 (1) No 13 No 





3 Female 69 D1 
Lift and 
snare 
9 8 1 (1) No 38 No 




3 3.5 1 (1) No 82 Yes 









5 n/a † n/a 
†
 No
 64 No 
7 Female 75 D1 RBL ER 7 8 1 (1) No 49 No 
8 Male 51 D1 
Lift and 
snare 
10 10 1 (1) No 81 No 
9 Male 60 D1 
Lift and 
snare 





10 Female 65 D2 
Lift and 
snare 
9 9 1 (1) No 21 No 
11 Male 63 D1 RBL ER 4 4 1 (1) No 58 No 
12 Female 59 D1 
Lift and 
snare 
10 8 1 (<1) No 20 No 
D1: first part of duodenum; RBL: Rubber band ligation; ER: endoscopic resection; G1: grade 1;  







 Incidental finding on surgical 
specimen Ampullary NET Functional tumours 















































































Treatment Surgery for primary pathology Surgery: 5 
Palliative care:1 
Surgery for primary 
pathology 
Primary pathology 
Duodenal GIST: 1 









Outcome 3 deaths from primary pathology 3 deaths due to 
metastatic NET † 
1 death but non-NET 
related 
M: male; F: female; D1: first part of duodenum; D2: second part of duodenum; UK: unknown; G1: grade 1; G2: 
grade 2; G3: grade 3 



































1 62 Male 43 3 D1 2 3 0 No No  
2 73 Male 24 3 D1 
Insufficient 
sample 
5 5 Yes No  
3 76 Male 3 1 D1 4 15 15 Yes No  
4 51 Male 7 1 D1 1-2 10 10 Yes No  
5 64 Male 30 2 D2 
Insufficient 
sample 
5 0 No No  
6 57 Female 54 4 D1 1 5 0 No No  
7 81 Male 70 6 D1 1 8 5 Yes No  
8 72 Female 15 2 D1 1 5 0 No No  
9 67 Male 21 1 D1 1 1 1 Yes No  
10 71 Male 98 7 D1 1 10 10 Yes No  
11 59 Female 43 2 D1 1 5 3 Yes No  
12 73 Male 59 4 D1 1 6 2 Yes No  
13 52 Male 38 2 D1 1 8 8 Yes No  
14 62 Male 33 4 D1 2 10 0 No No  
15 61 Female 49 5 D1 1 3 0 No No  
16 45 Male 52 5 D1 8 5 0 No No  
17 82 Female 69 5 D1 1 6 2 Yes No  
18 67 Male 28 2 D1 1 7 7 Yes No  
19 68 Male 30 2 D1 <2 12 20 Yes 





20 49 Female 7 1 D2 2 8 8 Yes No  
21 63 Male 20 2 D1 2 8 8 Yes No  
22 74 Female 6 1 D1 1 2 0 No No  
27 
 
23 49 Female 26 1 D1 <1 3 0 No No  
24 70 Female 20 1 D1 2 10 13 Yes EMR 
25 49 Female 49 5 D1 1 3 0 No No  
26 71 Male 18 2 D1 <2 8 3 Yes No  
27 79 Male 8 1 D1 1 3 3 Yes No  
28 78 Female 15 2 D1 1 2 3 Yes No  
29 59 Male 3 1 D1 1-2 4 2 Yes No  
30 70 Male 4 1 D1 <2 5 5 Yes No  
 
 
